Drug-Linkers in Antibody–Drug Conjugates: Perspective on Current Industry Practices-Reference-Cited by-同舟云学术

Drug-Linkers in Antibody–Drug Conjugates: Perspective on Current Industry Practices

Published:2023-06-29 Issue:7 Volume:27 Page:1248-1257
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Bulger Paul G.¹^ORCID,Conlon David A.²^ORCID,Cink Russell D.³^ORCID,Fernandez-Cerezo Lara⁴^ORCID,Zhang Qunying⁵,Thirumalairajan Srinath⁶,Raglione Thomas⁷,Liang Ruiting⁸,Zhou Jinsheng⁹,Chalgeri Arun¹⁰

Affiliation:

1. Department of Analytical Research & Development, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States

2. Conlon Pharma Consulting, Easton, Pennsylvania 18045, United States

3. Process Research & Development, AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States

4. Department of Process Research & Development, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States

5. Analytical Research & Development, AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States

6. Chemical Process and Analytical Development, Seagen Inc., 22515 29th Dr SE, Bothell, Washington 98021, United States

7. Chemical Process Development, Bristol-Myers Squibb, New Brunswick, New Jersey 08903, United States

8. Analytical Research & Development, BeiGene, Inc., 30 Science Park Road, Beijing 102206, China

9. Synthetic Molecule Design and Development, Eli Lilly and Company, Indianapolis, Indiana 46225, United States

10. Regulatory Affairs CMC, Daiichi Sankyo Inc., 211 Mount Airy Road, Basking Ridge, New Jersey 07920, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.3c00136

Reference45 articles.

1. Please visit www.iqconsortium.org for more information.

2. New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products. https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products (accessed December 29, 2022).

3. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy

4. Antibody drug conjugate: the “biological missile” for targeted cancer therapy

5. Unlocking the potential of antibody–drug conjugates for cancer therapy

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody–drug conjugate development;Drug Discovery Today;2024-08

2. Risk Assessment and Control of N-Nitrosamines in Antibody–Drug Conjugates: Current Industry Practices;Organic Process Research & Development;2024-07-30

3. AJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Selective Antibody–Drug Conjugate Synthesis;Organic Letters;2024-04-19

4. Modified Sol-Gel Method of Synthesising a Mn4+-Doped Mg2TiO4: A Red Phosphor for Improved LED Performance;Annales de Chimie - Science des Matériaux;2024-02-26

5. A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy;Frontiers in Pharmacology;2023-09-18